Drug Profile
Nisevokitug - Novartis
Alternative Names: Anti-TGF beta antibody - Novartis; NIS-793Latest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator XOMA
- Developer Novartis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Myelofibrosis
- Phase I Myelodysplastic syndromes
- No development reported Solid tumours
- Discontinued Pancreatic cancer
Most Recent Events
- 01 Nov 2023 Discontinued - Phase-II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Taiwan, Switzerland, Spain, Singapore, Italy, France, Czech Republic, Belgium, USA, Austria, United Kingdom, Germany, Japan, Finland (IV) (NCT05546411)
- 01 Nov 2023 Discontinued - Phase-III for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Australia (IV) (NCT05546411)
- 09 Mar 2023 XOMA has patent protection and patent aplications for nisevokitug in USA, EU and Japan